Skip to main content

Checking the Pulse: New Updates for Q2 2024

By July 9, 2024No Comments

Enrollment Completed in the DEEPER REVEAL Clinical Trial

We want to thank everyone who worked to complete enrollment in the DEEPER REVEAL clinical trial (NCT05358353) to evaluate Spur™ Retrievable Scaffold Therapy (RST), which was designated a Breakthrough Device by the FDA. The study enrolled 130 patients in over 35 clinical centers in the U.S.

Read the press release

Our New European Division: Reflow Medical Europe GmbH

We’re pleased to introduce the members of our newly formed team of professionals in Europe. Knut, Dejan and Harry are working toward the European launch of the revolutionary Spur™ RST and bringing the Reflow Wingman™ and Spex® to physicians in Europe.

Meet Reflow’s executive team

Reflow’s Successful Educational Efforts at LINC 2024

Our first-ever educational event at The Leipzig Interventional Course in Leipzig, Germany on May 28 drew a good crowd! “Innovations in CLTI: Exploring Spur Retrievable Scaffold Therapy” was moderated by Jos van den Berg, M.D., Ph.D., with panelists Thomas Zeller, M.D., Marcus Thieme, M.D. and Marianne Brodmann, M.D. Three presentations on Spur Retrievable Scaffold Therapy and a live case were also well attended.

Reflow Team at NCVH 2024

The 25th Anniversary of the New Cardiovascular Horizons (NCVH) Annual Conference was held May 23-25, 2024 in New Orleans, LA. Dusty Latiolais, Moniq Anderson, Guenter Haines and Chris Gebhardt attended from Reflow.

Case Study: Wingman™ Crosses Long SFA CTO

Dr. Rao reports on the successful revascularization of the right SFA and popliteal artery using the Reflow Wingman.

Read the report






U.S. Limited Market Release: SINC™ Catheters

The 510-K approved SINC™ support catheters are easy to use, highly versatile and low-profile devices used with guidewires to access the peripheral vasculature, facilitate placement and exchange of guidewires and other devices, and provide a conduit for delivering saline solutions or diagnostic/therapeutic agents.

Q3 – ’24 Conferences